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Abstract
In its basal state, KEAP1 binds the transcription factor NRF2 (Kd = 5 nM) and promotes its degradation
by ubiquitylation. Changes in the redox environment lead to modification of key cysteines within
KEAP1, resulting in NRF2 protein accumulation and the transcription of genes important for restoring
the cellular redox state. Using phage display and a computational loop grafting protocol, we engi-
neered a monobody (R1) that is a potent competitive inhibitor of the KEAP1–NRF2 interaction. R1
bound to KEAP1 with a Kd of 300 pM and in human cells freed NRF2 from KEAP1 resulting in activa-
tion of the NRF2 promoter. Unlike cysteine-reactive small molecules that lack protein specificity, R1 is
a genetically encoded, reversible inhibitor designed specifically for KEAP1. R1 should prove useful
for studying the role of the KEAP1–NRF2 interaction in several disease states. The structure-based
phage display strategy employed here is a general approach for engineering high-affinity binders
that compete with naturally occurring interactions.
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Introduction
NRF2 (nuclear factor erythroid 2-related factor 2) is a transcription
factor that serves as a key modulator of cellular oxidative environment
(Nguyen et al., 2009). Under basal conditions, NRF2 binds the Kelch
domain of homodimeric KEAP1 (Kelch-like ECH-associated protein
1) through its high-affinity (Kd 5 nM) and low-affinity motifs
(Kd 1 μM) (Lo et al., 2006; Tong et al., 2006). KEAP1, via its BTB
domain, also binds CUL3 and recruits NRF2 to the CUL3-RING
E3 ligase complex for ubiquitylation and subsequent degradation
(Fig. 1A) (Nguyen et al., 2009). Under oxidative stress, cysteine
residues on KEAP1 are modified resulting in inhibition of NRF2
ubiquitylation (Taguchi et al., 2011). As a result, NRF2 accumulates
and translocates to the nucleus where it initiates transcription of a
myriad of cytoprotective genes.
Activation and deactivation of NRF2 have been implicated in a
variety of disease states. Activation of the NRF2 defense response has
been shown to protect against neurodegenerative diseases, inflamma-
tion, cardiovascular disease, diabetes and the initiation of cancer
(DeNicola et al., 2011). However, it has also been shown that NRF2
activation can protect cancer cells from oxidative stress, chemothera-
peutic agents and radiotherapy (Ohta et al., 2008; Hayes et al., 2010;
DeNicola et al., 2011). Indeed, a variety of loss-of-function mutations
in KEAP1 that lead to NRF2 activation have been discovered in human
cancers (Hast et al., 2014).
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Regulation of NRF2 via pharmaceuticals has been proposed for the
treatment of several diseases (Magesh et al., 2012). A NRF2-activating
compound, dimethyl fumarate, was recently approved by the Federal
Drug Administration for the treatment of multiple sclerosis (Moharregh-
Khiabani et al., 2009). Many NRF2-activating molecules, including
dimethyl fumarate, function by covalently modifying cysteines on
KEAP1, which leads to lower rates of NRF2 ubiquitylation (Zhang
and Hannink, 2003; DeNicola et al., 2011). These molecules are not
specific for KEAP1, but rather non-discriminately react with activated
cysteines on a variety of proteins via oxidation or alkylation reactions
(Zhang and Hannink, 2003). Several chemical groups are adept at
this reaction includingMichael acceptors, oxidizable quinones, isothio-
cyanates and vivinal dimercaptans. Many of these groups are found in
naturally occurring, plant-derived phytochemicals that have been
shown to activate the NRF2 pathway (Hayes et al., 2010). Although
they are clearly useful for activating NRF2, these molecules do not pro-
vide precise tools for probing the KEAP1/NRF2 pathway. As they are
reactive toward many proteins in a cell, observed phenotypes may be
due to a variety of factors. To create a molecule that can more specific-
ally probe the function of KEAP1, we engineered a protein that binds
tightly to KEAP1 and competitively inhibits NRF2 binding.
Proteins have proved more effective at inhibiting protein–protein in-
teractions than small molecules, as they are more adept at binding large
surfaces (Arkin andWells, 2004; Schön et al., 2011). One approach for
creating an inhibitor is to structurally mimic the naturally occurring
interface that you are trying to inhibit. Most straightforwardly, this
can be achieved by using a re-engineered version of one of the binding
partners as the inhibitor. Typically, the natural binder is modified so
that it no longer activates the endogenous signaling pathway. For
instance, the extracellular portion of a cell surface receptor when
expressed alone can bind signaling molecules and prevent them from
activating the functional receptor (Peppel, 1991; Moreland, 1998).
Directed evolution techniques like phage display or yeast display can
be used to identify mutations that increase the affinity of the inhibitor
for the target, and therefore allow the re-engineered version to
outcompete the naturally occurring binding partner. However, in
some cases, it may be advantageous to use an alternative protein as
the scaffold for inhibitor design, for example, when there is a need
for more improved expression, stability, solubility or pharmacokinetic
properties.
When using unrelated protein scaffolds to design inhibitors,
mimicry of the target interface can still be used to gain affinity and
specificity (Richards et al., 2003). Schief et al. have developed a com-
putational grafting protocol that searches the protein database for
proteins that can orient a set of surface residues in a manner that
superimposes with residues from the target interface (Ofek et al.,
2010; Azoitei et al., 2011). Using this approach, they have grafted
antigen epitopes into scaffolding molecules in a manner that promotes
binding to target antibodies and potentially function as vaccines.
Recently, we developed a grafting protocol in the molecular modeling
program Rosetta, called AnchoredDesign, for use with scaffolds that
have surface exposed loops amenable to mutation (Lewis and
Kuhlman, 2011). In this approach, a contiguous set of binding-critical
interface residues from a binding partner of the target protein are in-
serted into one of the loops of the scaffold. These residues serve as an
anchor point for the interaction. Surrounding residues and loops are
further optimized using computational or screening techniques.
Potential advantages of the anchored design approach versus screen-
ing with naïve loop libraries are that the binding site and orientation
can be pre-specified and that it allows for creating libraries that are
enriched in binders, increasing the probability that a tight binder
will be identified.
The structure of the KEAP1–NRF2 interaction makes it well suited
for the anchored design protocol. In the bound complex, a flexible
region of NRF2 inserts into a large pocket on the Kelch domain of
KEAP1 (Fig. 1B). Peptides derived from this region of NRF2 bind to
KEAP1 with an affinity of ∼100 nM (Chen et al., 2011; Hancock
et al., 2013) and can serve as an excellent anchor for insertion into
a scaffolding protein. As a scaffold, we used the 10th type III domain
of human fibronectin (FN3), an IgG-like β-sandwich protein that has
Fig. 1 The KEAP1–NRF2 interaction. (A) NRF2 binds to the Kelch domain of homodimeric KEAP1 via high-affinity (DEETGE) and low-affinity binding motifs
(DLG). KEAP1 also binds to the E3 ubiquitin ligase, Cullin3 (CUL3), which leads to ubiquitylation of NRF2. (B) A crystal structure of the KEAP1 Kelch domain
bound to a 16mer peptide from NRF2, drawn from PDB 2FLU (Lo et al., 2006). The binding motif is highlighted in sticks. The KEAP1 surface is colored according
to electrostatic charge. A black highlight shows the unfilled portions of the pocket targeted with the non-anchor loop by the AnchoredDesign protocol. (C) A crystal
structure of 10th type III domain of human fibronectin with the FG loop colored as red (used as the anchor loop in our design procedure) and the BC loop.
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three complementary determining region (CDR)-like flexible loops
(BC, DE and FG loops) that are highly tolerant to mutagenesis
(Batori et al., 2002). Fn3 variants, often called monobodies, have
been engineered to bind a wide array of target molecules using selec-
tion strategies such as phage display (Koide et al., 2012). Unlike anti-
bodies, the domain is monomeric and does not contain any disulfides
and is therefore more stable in the reducing environment of a cell. To
engineer a monobody that binds to KEAP1, we grafted a portion of a
NRF2 peptide into the FG loop of FN3 and then used molecular mod-
eling and phage display to optimize surrounding residues on the FG
loop and the BC loop for enhanced affinity toward KEAP1. The tight-
est binder identified with these approaches binds to KEAP1 with an
affinity of 300 pM, outcompetes wild-type NRF2 for binding to
KEAP1, and activates NRF2-mediated transcription in living cells.
Experimental procedures
Computational design of anchor-FG loop and BC loops
Computational modeling of monobody–KEAP1 complexes proceeded
in two stages. First, the Rosetta protocol AnchoredPDBCreator was
used to create starting models for the design simulations (Lewis and
Kuhlman, 2011). Second, flexible-loop design simulations were per-
formedwithRosetta protocol AnchoredDesign to search formonobody
loop sequences compatible with the inserted anchor conformation and
KEAP1 binding.
AnchoredPDBCreator was used to create intermediate models
containing structural data from two sources (Fig. 2, top). First, the
KEAP1 Kelch domain with associated NRF2 peptide was sourced
from PDB 2FLU, a 1.5 Å resolution structure of this complex
(Lo et al., 2006). Second, the Fn3 scaffold was sourced from PDB
1FNF, a 2 Å resolution structure containing the 7th through
10th type III domains of human fibronectin (Leahy et al., 1996).
AnchoredPDBCreator was used to combine the two structures such
that loop residues of the Fn3 domain were overwritten with the con-
formation and identity of the NRF2-derived peptide. This chimerawas
then placed next to the KEAP1 Kelch domain such that the copied an-
chor residues were in their correct placement relative to the binding
interface. Minor loop refinement of the non-anchor portion of the
loop was then performed to resolve any major clashes between the
Fn3 scaffold and KEAP1 (Fig. 2, top). The key data in this intermedi-
ate model are that the anchor and target structures maintain their crys-
tallographic conformation even while the anchor has been embedded
into a loop of the scaffold protein.
Given that we were performing flexible-backbone loop design, it
was not obvious to us what loop lengths, anchor sequences or anchor
placements within the loops are appropriate. We tested two different
NRF2-derived anchor sequences, DEETGE and ETGE, in several loop
placements and lengths (Supplementary Table SI).
In the second computational stage, design simulations were
performed with Rosetta’s AnchoredDesign protocol (Lewis and
Kuhlman, 2011). AnchoredDesign implements the anchored design
idea by remodeling both the sequence and conformation of surface
loops of a scaffold protein while maintaining the embedded crystallo-
graphic anchor–target interface. Anchor residues are held fixed both
internally and relative to the scaffold protein. Loop residues in the
non-anchor loops are remodeled with Rosetta’s implementations of
the cyclic coordinate descent (Wang et al., 2007) and kinematic loop
closure (Mandell et al., 2009) algorithms. Non-anchor residues in the
anchor-containing loop can be remodeled with these same algorithms,
provided that the internal degrees of freedom of the anchor residues are
not visible as variable to the loop remodeling algorithms, and Rosetta’s
internal coordinate foldingmechanism ismodified appropriately (Wang
et al., 2007; Lewis and Kuhlman, 2011). Other residues near the
interface are given the freedom to relax their side chain but not change
sequence. Residues far from the interface are not modified.
An initial batch of models for each loop length and anchor place-
ment in Supplementary Table SI were created. Each of these experi-
ments produced ∼1000–1500 models of varying sequences and
conformations. The best-scoring and structurally interesting or distinct
models from the first round were used as inputs for another round of
modeling that focused on only small perturbations to the protein back-
bone (Fig. 2, middle portion). Top scoring sequences from this round
were used to create the directed library described in results (Fig. 2, bot-
tom portion). See the Supplementary Methods for the Rosetta com-
mand line options used for both rounds of modeling.
Library construction
Both the directed-BC and randomized-BC libraries were constructed
using Kunkel mutagenesis as fusions with the pIII protein from fila-
mentous bacteriophage M13 and a DsbA signal sequence (Fellouse
et al., 2007; Wojcik et al., 2010). Twenty-eight mutagenic oligonu-
cleotides (Supplementary Table SII) encoding for the designed BC
loops were pooled to have an equimolar solution of all 587 BC loop
sequences. One hundred µM of either the oligonucleotide mixture for
the directed-BC library or the single mutagenic oligonucleotide that
Fig. 2 Protocol flow chart. This flow chart outlines the combined computational
and experimental protocol used to identify tight binders to KEAP1. See also the
Supplementary Methods for command lines. At the top are two steps
performed inside the AnchoredPDBCreator protocol. In the middle are steps
performed in the AnchoredDesign protocol. Note that the middle step loops
on itself. Here, we performed two cycles of the AnchoredDesign modeling.
The bottom portion represents data analysis and translation of modeling
results into phage display libraries, followed by experimental validation.
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encodes for 7 NNK degenerate codons to create the randomized-BC
library was 5′-phosphorylated with 20 units of T4 polynucleotide ki-
nase in the presence of 1 mM ATP, 5 mM DTT, 10 mM MgCl2 and
50 mM Tris–HCl pH 7.5. Phosphorylated oligos were annealed to
20 μg of uracil-incorporated single-stranded phagemid with 5:1
oligo:template ratio in the presence of 10 mM MgCl2 and 50 mM
Tris–HCl pH 7.5 by cooling from 90°C to 30°C over 50 min followed
by incubation at least 5 min at 4°C. Annealed oligonucleotides were
extended with 30 units of T7 DNA polymerase and the heteroduplex
DNAwas ligated with 2 kU of T4 DNA ligase by incubation at 20°C
for 3 h in the presence of 0.85 mM each dNTP, 0.33 mM ATP, 5 mM
DTT, 10 mMMgCl2 and 50 mMTris–HCl pH 7.5. Desalted reaction
products were transformed into electrocompetent SS320 cells. Pooled
transformed bacteria were expanded into 500 ml 2× TY medium sup-
plemented with 100 μg/mL ampicillin and 1010 pfu/mL M13K07
helper phage. Phage library was produced by shaking (225 rpm) for
16 h at 37°C. Prior to superinfection with the helper phage, serial di-
lutions were plated to estimate library size. Phage was precipitated and
quantified as described (Fellouse et al., 2007).
Library selections
Purified His-tagged KEAP1 was chemically biotinylated targeting
three amine groups (N-terminus and two lysine residues) with
20-fold excess E-Z link Sulfo-NHS-LC-Biotin (Pierce 21335) in phos-
phate-buffered saline (PBS)/5 mM β-mercaptoethanol pH 7.4 buffer at
4°C. After 3 h, reaction products were desalted using a PD-10 column
to remove excess biotin. Biotinylated protein was serially dialyzed
twice against 500× volume of PBS/5 mM β-mercaptoethanol pH 7.4
buffer to remove trace biotin.
For the first three rounds of biopanning, streptavidin magnetic
beads were pre-blocked overnight at 4°C with 0.5% w/v bovine
serum albumin (BSA) in PBS, saturated with biotinylated KEAP1
(15–150 nM) and incubated with phage (5 × 1011–1013) pre-adsorbed
with pre-blocked, but uncoated beads. Beads were washed 10 times,
and bound phage was eluted with 0.2 M glycine/HCl 5 mg/mL BSA
pH 2.2 solution. For Rounds 4 thru 6, pre-adsorbed phage (1010–
1011) was first incubated with biotinylated KEAP1 followed by cap-
ture with blocked streptavidin beads. Beads were washed 15–20
times before bound phage was eluted as above. After each round, log-
phase SS320 cells were infected with the eluted phage followed by
superinfection with the helper phage to amplify the phage for the
next round.
Protein expression and purification
All Fn3 variants were cloned into pGEX-4T-1 (GE Healthcare
28-9545-49) vector via BamHI and XhoI restriction sites. Proteins
were expressed as a C-terminal fusion to glutathione-S-transferase
(GST). Cells were lysed in PBS supplemented with 1 mMphenylmethyl-
sulfonyl fluoride. GST-Fn3 fusions were purified from cleared lysates
using pre-packed 5 ml glutathione columns (GEHealthcare). The eluate
was treated for 2 days with 50 units of thrombin (Sigma) to cleave the
GST away. The proteolyzed sample was concentrated and applied to
Superdex-75 Hi-load 16/60 gel filtration chromatography column
(GE Healthcare) to separate Fn3 from GST and thrombin. The free
Fn3 variants were used in affinity and stability measurements, whereas
GST-fused form was dialyzed twice against PBS to remove glutathione
and used in pull-down experiments.
The Kelch domain of KEAP1was expressed using a pET15b-based
expression plasmid with a N-terminal His-tag followed by a thrombin
cleavage site (Lo et al., 2006). The expressed protein was purified by
His-tag affinity chromatography followed by anion exchange. Finally,
the protein was refined using Superdex-75 Hi-load 16/60 gel filtration
chromatography.
For the co-purification of the Kelch domain in complex with R1, ex-
pression plasmids encoding the GST-R1 fusion and His-Kelch were co-
transformed into BL21(DE3)pLysS cells. After an hour of recovery in
super optimal brothmedium, cells were transferred to a shake flask con-
taining 30 ml of 2× TY/ampicillin medium. After 5 h, cells reached the
log phase and were transferred to the 3-l LB/ampicillin medium.
Following another 3 h of growth, cells were induced with isopropyl
beta-D-1-thiogalactopyranside at 20°C for overnight expression. The
GST-tagged R1 complexed with Kelch domain was first purified by
glutathione affinity chromatography. The eluate was concentrated
and resolved by Superdex 200 column. Fractions containing Kelch do-
main and GST-R1 fusion were treated with 50 units of thrombin to re-
move the His- and GST tags. The products were passed through
glutathione column twice to remove GST and uncleaved GST-R1.
The flow-through was resolved with Superdex-75 column to recover
Kelch-R1 complex.
All proteins were purified to >90%. Concentrations were deter-
mined using A280 readings and extinction coefficients predicted by
ProtParam.
Isothermal titration calorimetry
Purified Fn3 variants and Kelch domain were dialyzed in the same
container against the ITC buffer (20 mM KH2PO4, 150 mM NaCl,
5 mM β-mercaptoethanol, pH 7). The post-dialysis buffer was also
used as the diluent for all experiments. All titrations and measure-
ments were performed using the MicroCal Auto-iTC system (GE
Healthcare). Twentymicroliters of 200–300 μMFn3 variant is titrated
in 10 successive injections to the cuvette containing 6–15 μM Kelch.
Data were fitted to the one-site binding curve to derive the Kd values.
Competitive fluorescence polarization experiments
All fluorescence polarization (FP) experiments were conducted using a
Jobin Yvon Horiba FluoroMax3 fluorescence spectrometer. TAMRA-
labeled peptides (produced by UNC Peptide Core Facility) were excited
with polarized light at 555 nm, and the polarization of emitted light
was measured at 583 nm. Titrations were performed with 20 nM pep-
tide and 350 nM KEAP1 in the starting solution; this represents
∼80% bound peptide as determined by peptide-KEAP1 experiments.
Monobodywas then titrated into the cuvette and polarizationmeasured
after each addition. These data were fit for IC50 using a procedure re-
ported by Lungu et al. (2012) and refined intoKi with an Internet-based
calculator (Nikolovska-Coleska et al., 2004). Certain experiments vio-
late the assumptions of Lungu et al., and fits were generated from an
iterative numeric fitting program adapted from Purbeck et al. (2010).
Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed using a
BIORAD Proteon XPR36 biosensor. Fifty nM biotinylated KEAP1
(via lysine modification) was captured on a streptavidin-coated sensor
chip, and sensorgrams were collected at varying concentrations of R1.
Circular dichroism
Thermal melts were performed using a Jasco J-815 circular dichroism
instrument, with 20 μMR1 orwild-type Fn3 in 20 mMKH2PO4 pH 7
buffer.
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Cell-based luciferase assays
R1 and FN3wild type (WT) were gateway cloned into a mammalian ex-
pression CMV-Phage-Flag Gateway vector using pCR8/GW/TOPO TA
Cloning Kit (Invitrogen). HEK293T cells weremaintained in Dulbecco’s
modification of Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS; Hyclone) in a 37°C humidified incubator with 5%
CO2. Transfection of expression plasmids was done with Lipofectamine
2000 (Invitrogen). HEK293T cells were transiently transfected in
48-well format with expression constructs, Flag-R1, Flag-Fn3 WT,
FLAG-KEAP1, FLAG-NRF2, hQR41-ARE luciferase and a control
plasmid containing Renilla luciferase driven by a constitutive cyto-
megalovirus (CMV) promoter. Approximately 24 h post-transfection,
NRF2-mediated transcription was measured as the ratio of firefly to
Renilla luciferase activity (Promega Dual-Luciferase Reporter Assay
System). Values shown are the mean normalized relative light units
(RLU) from one representative experiment of three biological replicate
experiments.
Western blotting and immunoprecipitations
HEK293T cells were lysed in 1% Triton buffer [1% Triton-X, 10%
glycerol, 50 mM Tris–HCl, 150 mMNaCl, 2 mM EDTA supplemen-
ted with protease and phosphatase inhibitors (Thermo Scientific)] for
30 min on ice. Lysates were cleared by 10 min centrifugation at full
speed. An input of 10% was taken, and the remaining lysate was di-
vided into six immunoprecipitations (APs): beads only, 1 μg GST-Fn3
WT, or 0.1, 0.25, 0.5 or 1 μg of GST-R1 protein. APs were completed
using 30 μl each of glutathione affinity beads (GE Healthcare), rotat-
ing for 1 h at 4C. Streptavidin affinity purifications (APs) were com-
pleted similarly to GST-APs, except using streptavidin beads (GE
Healthcare) and these complexes were purified from HEK293T cells
stably expressing SBPHA-KEAP1. APs were washed three times with
lysis buffer, and bound proteins were eluted from the beads using
SDS–PAGE sample buffer. Lysates were resolved on 4–12% SDS–
PAGE gels (Invitrogen), transferred onto nitrocellulose membranes
and probed overnight at 4°C with the following antibodies: KEAP1
(Protein Technologies, 10503-2-AP), GST (Cell Signaling, 2622),
β-actin (Sigma, A2066), FLAG (Sigma, M2), NRF2 (Epitomics,
62352) and HO-1 (Abcam, 13243). Secondary HRP-conjugated anti-
bodies (Jackson Laboratories) were applied at 1:10 000 dilution for
30 min at room temperature. Western blots were developed using
the Pierce ECL western blotting reagent (Thermo Scientific). Data
shown are representative experiments from 2 to 3 biological replicates.
Results
The acidic NRF2 peptide (-DEETGE-) docks into a large positively
charged pocket on KEAP1. It occupies roughly half of the volume
of the pocket, while the rest of the space is filled with water (Fig. 1B)
(Lo et al., 2006). We hypothesized that we could create a
KEAP1-binding monobody by building the DEETGE sequence into
one loop of a monobody, and then use a neighboring loop in the mono-
body to fill the rest of the pocket on KEAP1. To determine which loops
on the monobody are best positioned for this approach, we performed
molecular docking experiments with the AnchoredDesign protocol in
Rosetta. In this protocol, the anchor sequence, in our case the NRF2
peptide, is inserted into one of the monobody loops and the sequence
and conformation of neighboring monobody loops are optimized for
binding against the target (Fig. 2). Previous work has shown that the
BC and FG on monobodies are tolerant to mutagenesis and that they
form an effective surface for binding proteins (Koide et al., 2012).
We computationally tested 11 alternative loop lengths and anchor
positions for the BC and FG loops, with anchor sequences of ETGE or
DEETGE (Supplementary Table SI). A high-resolution crystal struc-
ture of the NRF2 peptide bound to KEAP1 (pdb code: 2FLU) was
used as the starting point for the simulations. During these simula-
tions, the coordinates and sequence of the anchor residues were held
fixed, while surrounding residues in the anchor loop were allowed to
sample alternative conformations and sequences in order to accom-
modate the anchor residues into the monobody scaffold. The position
of the anchor residues was not varied with respect to the binding part-
ner, KEAP1, but the rest of the monobody scaffold adopted different
relative orientations with respect to the target as the connections
between the anchor and monobody were perturbed. In this respect,
the protocol is best described as a tethered-docking simulation.
For each of the alternative loop lengths and anchor positions in
Supplementary Table SI, ∼1000–1500 independent trajectories were
performed to identify low-energy sequence/structure pairs. The result-
ing models were then ranked by the total energy of the complex, quality
of contacts at the interface and loop metrics (Lewis and Kuhlman,
2011). Several dozen low-energy models were selected for further
study. All of these models used an anchor inserted into the FG loop
of FN3: although we tested BC loop insertions of an ETGE anchor,
no models scored well after the first round in AnchoredDesign. These
selected models each seeded another 1000–1500 AnchoredDesign
runs aimed at generating smaller perturbations. We then examined
the lowest scoringmodels from this second round of design to determine
if there was an anchor position and loop sequence that was overrepre-
sented in the lowest scoring models. We determined that one such se-
quence was yavRDEETGEFHWPis. Here, lowercase indicates
constant Fn3 sequence for framing, the underline indicates the anchor
and other capital letters indicate design positions. The post-anchor
phenylalanine residue happens to be the NRF2 residue immediately fol-
lowing the ETGE sequence as well; this represents Rosetta’s conver-
gence onto biology but was indeed a designed position. The final
designed proline residue is native to the scaffold, but again was allowed
to vary during the design simulation. For reference, this anchor se-
quence is compatible with label BC plus 1, 6_77.83 in Supplementary
Table SI. The anchor loop sequence requires a one-residue deletion in
the Fn3 FG loop, and the accompanying low-energy BC loop sequences
included a single insertion. Our database of models contained 7181
structures that converged to this particular anchor loop sequence, but
with a diverse set of sequences and conformations for the BC loop.
The DE loop did not make significant contact with KEAP1 in any of
the low-energy designs.
The diverse set of BC sequences prompted us to design two
combinatorial libraries from which we sought to select tight binders.
In both libraries, the sequence of the FG loop was set to the
design-obtained sequence RDEETGEFHWP. The first library was a
directed library based on the low-energy models produced during
the anchored design simulations. This directed library involved 587
different BC loop sequences and includes BC sequences from the top
80 computational models. The other 507 loop sequences in this li-
brary were highly similar to the top 80 designs (Supplementary
Table SII). In parallel, we constructed a randomized library where
seven positions in the BC loop were randomized using the degenerate
codon NNK, for a theoretical size of 3.4 × 1010 alternative DNA se-
quences. This library served as a control to gauge the level of modeling
success and as another potential source of a potent competitive inhibi-
tor. It is important to note that this library is still directed in the sense
that we have fixed the anchor sequence and site. The experimental size
of the randomized library was ∼2 × 1010, and therefore, there was a
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∼59% chance that a particular DNA sequence was sampled during
selection. For both libraries, we used phage display to select for high-
affinity binders as the FN3 scaffold has been shown to express robustly
on the surface of phage. Following several rounds of biopanning, we
sequenced clones from the directed library to assess library diversity.
The library did not converge to a few clones, suggesting that the
affinities of the winner clones were comparable, or that the selective
pressure was not stringent relative to the affinity of many of the best
binders in the pool. Among the selected clones from the directed
library, we chose a few that were either exact BC sequences produced
by the design simulations or were only a mutation or two away from a
designed sequence (Supplementary Table SII). For the randomized
library, we isolated a few winner clones that yielded high phage titers
under highly stringent conditions indicative of high affinity for the
target.
We purified the selected clones andmeasured affinity for the KEAP1
Kelch domain using isothermal titration calorimetry (ITC) (Fig. 3A) and
a competitive FP assay where the FN3 variants competed with the fluor-
escently labeled NRF2 peptide for the Kelch domain of KEAP1
(Fig. 3B). This assay, in addition to quantifying affinity, is useful to val-
idate that FN3 variants are binding the target-binding surface on
KEAP1, and that binding should be competitive with NRF2 binding.
For the affinity range of 0.1–1 μM, the two methods yielded compar-
able values. For tight binders, however, ITC was not as sensitive. In
this case, we relied on the competitive FP assay to determine Kd and
also measured the binding affinity of the tightest binder with SPR
(Fig. 3C).
The affinity wemeasured for the isolatedNRF2 peptide for KEAP1
(Kd = 141 nM) was consistent with published results (Hancock et al.,
2013). An FN3 construct, wtBC, with the computationally designed
FG loop containing the DEETGE sequence and a naïve BC loop had
10-fold decreased affinity (Kd = 1.56 uM) relative to the source peptide
(Table I). We next examined the binding affinities of Fn3 variants se-
lected from our directed and randomized libraries. The selected clones
from the directed library showedmodest improvements over our wtBC
control, and had affinities ranging from 100 to 850 nM. To examine if
the improvements in binding affinity were due to the computationally
designed interactions in the BC loop, we performed alanine mutagen-
esis on BC loop residues of D1 and D4 that were predicted by the
Rosetta modeling to form favorable interactions with the positively
charged groove on KEAP1. Alanine mutagenesis did not significantly
perturb binding affinities, suggesting that these designed contacts were
not forming as designed or were not energetically favorable.
In contrast to the directed library, the two clones isolated from the
randomized library showed dramatic increases in binding affinity. In
particular, the clone R1, had aKd of 300 pM, which is 5000-fold tigh-
ter than our wtBC control ‘starting point’ and 15-fold tighter than the
reported affinity for the interaction of full-length NRF2 for KEAP1
(5 nM) (Tong et al., 2006). As expected for a binding affinity in this
range, R1 and KEAP1 co-elute when run on a gel filtration column.
Encouraged by the tight binding between R1 and the Kelch domain,
we next tested if (i) R1 binds KEAP1 in human cultured cell lines, (ii) R1
expression increases NRF2 protein levels and (iii) R1 activates
NRF2-dependent transcription. First, protein lysate from HEK293T
cells was spiked with different amounts of the GST-wt-Fn3 or
GST-R1 recombinant proteins. GST pull-down with glutathione
beads followed by western blot analysis revealed that R1 captured
KEAP1, whereas Fn3 WT did not (Fig. 4A). Second, we expressed
FLAG-tagged Fn3 WT or FLAG-R1 in HEK293T cells stably expres-
sing SBP-tagged KEAP1 (Fig. 4B). Streptavidin AP of KEAP1 and sub-
sequent western blot analysis revealed associated FLAG-R1 but not
FLAG-Fn3 WT. These data suggest that R1 and KEAP1 co-complex
in cells. To evaluate whether R1 expression increased NRF2 protein le-
vels in cells, FLAG-R1 was overexpressed in HEK293T cells before
western blot analysis; NRF2 levels were moderately and reproducibly
increased by R1 but not FN3 WT (Fig. 4C). Last, we tested the impact
of R1 expression on NRF2-dependent gene expression. FLAG-R1 ex-
pression promoted NRF2-dependent transcription of the hQR41 firefly
luciferase reporter gene; this activation was dose dependent (Fig. 4D
and E). Consistent with this observation, expression of FLAG-R1 in
HEK293T cells increased the expression of heme oxygenase-1,
HMOX1, a NRF2 target gene (Fig. 4B).
Discussion
We tested two strategies for engineering the BC loop: design of specific
loop sequences with Rosetta (587 loop sequences) and phage display
Fig. 3 Biophysical characterization of R1 binding to KEAP1. (A) An ITC
experiment titrating R1 into a solution of 10 μM KEAP1 Kelch domain. (B) A
competitive FP assay titrating R1 into a sample containing the KEAP1 Kelch
domain pre-incubated with a fluorescently labeled peptide. R1 binding
dislodged the peptide and resulted in a decrease in FP. The data were fit
assuming single-site binding (Purbeck et al., 2010). (C) SPR data with KEAP1
Kelch domain immobilized on the sensor chip and R1 applied at the indicated
concentrations.
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with degenerate codons placed at each position in the BC loop. Not
surprisingly, the degenerate library produced the tightest binders as
over 1 billion sequences were probed with this approach. However,
it was disappointing that tighter binders were not identified among
the Rosetta designed loops. The tightest binder from the Rosetta de-
signed loops, D1, bound to Keap1 with an affinity similar to that
observed for free peptide. Additionally, alanine scanning of the BC
loop of D1 indicated that the side chains were not making strong
favorable interactions with Keap1. This result highlights the challenge
of performing accurate design and structure prediction with long loops.
Nature frequently uses loops to mediate protein–protein interactions,
but the most successful examples of computer-based design of pro-
tein–protein interactions have focused on interactions at more rigid sec-
ondary structural elements (Fleishman et al., 2011; Stranges et al.,
2011). It is interesting that simply inserting the binding epitope into
the FG loop led to ∼10-fold drop in binding relative to the free peptide.
Table I. Binding affinities of engineered monobodies and peptides for KEAP1 as measured by ITC, FP or SPR
BC loop FG loop ITC FP SPR
Controls Kd (nM) Kd (nM) Kd (nM)
wt APAVTV TGRGDSPASSK Undetectable
wtBC APAVTV RDEETGEFHWP 1555
Peptide – LDEETGEFL (182) 141 (322)
Directed library
D1 AWSYDEV RDEETGEFHWP 104 201
D2 GDLGTNT RDEETGEFHWP 116
D3 AWSYYEV RDEETGEFHWP 202
D4 GDGHEEI RDEETGEFHWP 849 690
D5 GDHHEDI RDEETGEFHWP 328
Randomized BC library
R1 RAYGYPS RDEETGEFHWP <3 0.3 0.30
For proteins D4 and D5, the underscored residue was in the directed library due to codon degeneracy and not the model database (see Supplementary Table SII).
For the NRF2-derived peptide, ITC and SPR measurements (shown in parentheses) are from the literature (Tong et al., 2006; Chen et al., 2011).
Fig. 4 R1 binds to cellular KEAP1 and activates NRF2-dependent transcription. (A) HEK293T lysates were subjected to AP with recombinant GST-R1 at various
concentrations (0.1–1.0 μg), GST-Wt Fn3 control (1.0 μg) or glutathione beads alone. Western blots demonstrate the amount of GST-tagged proteins and KEAP1
precipitated. (B) HEK293T cells stably expressing SBP-KEAP1 were transfected with FLAG-R1 at increasing DNA concentrations or with FLAG-Fn3 WT control
and subjected to AP for KEAP1. Western blots show the amount of KEAP1-complexed R1. (C) HEK293T cells were transfected with FLAG-R1 at increasing
concentrations of DNA or FLAG-Fn3 WT control before the western blot analysis. (D and E) HEK293T cells were transfected with the NRF2 transcriptional
reporter (hQR41) and CMV-driven Renilla luciferase, with varying amounts of FLAG-WT Fn3 or Flag-R1 plasmid. Nucleophosmin expression served as a
negative control. Data show the mean ± SD of relative luciferase units normalized to Renilla.
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This suggests that either the FN3 scaffold creates some strain when the
binding epitope adopts its bound conformation or that other elements
of the scaffold, for instance, the BC-loop, are disfavoring binding.
When combined with phage display, the anchored design strategy
was an effective approach for identifying tight binders against a spe-
cific binding site on KEAP1. The FN3 scaffold has three loops that are
highly tolerant to mutagenesis. However, it is experimentally impos-
sible to sample all permutations of amino acids on these loops. One
strategy for handling this problem has been to design libraries that
allow amino acids (i.e. A, S, Y, D) commonly observed in antibody
CDR sequences (Fellouse et al., 2007; Gilbreth et al., 2008). It is pos-
sible to identify tight binders from such libraries, and the binders will
often gravitate toward ‘hot spots’ on the target, but they are not guar-
anteed to bind the intended site on the target (DeLano, 2002). In these
cases to identify competitive inhibitors, one may need to co-incubate
the pool of binders with false targets lacking their proper interface
residues while selecting for the true target, or use expensive
semi-high-throughput screens that explicitly search for competitive
binding. If the target and the competitor are of high affinity, it is a chal-
lenging task to design a single sequence or chemically diverse library
that will yield both specific and tight binders that free the target from
the competitor chemical. The anchored design strategy guarantees a
biologically relevantmode of binding in addition to dramatically redu-
cing the library complexity required to achieve competitive inhibition.
In this particular case, exhaustive experimental search for the optimal
seven-residue BC loop is nearly within the technical limits of combina-
torial protein engineering, but searching exhaustively across multiple
FN3 loops at once was neither possible nor necessary. The computa-
tional and selection portions of this method were quite complemen-
tary in that the random library found higher affinity binders than
the computationally directed library, but the computationally identi-
fied FG loop sequence made construction of a random BC loop library
enriched in high-affinity binders straightforward.
We have used anchored design to create a competitive inhibitor
of KEAP1–NRF2 interaction. Full-length NRF2 binds KEAP1 via
two non-contiguous epitopes of which the high-affinity epitope
(-DEETGE-) is responsible for the majority of the binding energy to at-
tain an overall dissociation constant of nearly 5 nM. In order to
free NRF2 efficiently from KEAP1, we needed to design an FN3 variant
with sub-nanomolar affinity. Rosetta’s computational AnchoredDesign
protocol coupled with phage display yielded protein R1 that bound
KEAP1 with a Kd of 300 pM. To our knowledge, this is the first sub-
nanomolar peptide inhibitor of the KEAP1–NRF2 interaction (Chen
et al., 2011; Inoyama et al., 2012; Steel et al., 2012). Importantly, R1
is easily produced in bacteria, has a thermal stability comparable with
wild-type Fn3 and co-purifies with KEAP1 when co-expressed. When
spiked into mammalian cell extracts, R1 efficiently and specifically
captured KEAP1 in a dose-dependent manner. When expressed in
human cells, R1 induced higher NRF2 protein levels and activates
NRF2-driven transcription.
As a high-affinity competitive inhibitor of the KEAP1–NRF2 inter-
action and strong NRF2 agonist, R1 offers a new molecular tool with
translational potential. First, as a non-covalent KEAP1 inhibitor, R1
differs from cysteine-reactive small molecule activators. This promises
increased specificity and diminished off-target effects. Second, R1 and
other competitive inhibitors offer an elegant tool to further evaluate
KEAP1 function. For example, in addition to NRF2, several addition-
al proteins bind KEAP1 via an ETGE motif (i.e. WTX/FAM123B,
DPP3, MCM3) (Hast et al., 2013). It is probable that R1 will also
block the binding of these proteins to KEAP1, the consequences of
which are not yet known. Third, R1 and all competitive inhibitors
offer preventative therapeutic opportunities, with the caveat that the
intracellular delivery of proteins is still challenging. We found R1 to
bind KEAP1 with picomolar affinity, thus strongly supporting future
experiments that evaluate R1-driven cytoprotection. Fourth, R1 may
also provide a means to correct KEAP1 mutations in cancer.
Specifically, we previously demonstrated that ∼50% of KEAP1 muta-
tions found in lung squamous cell carcinoma bind NRF2, ubiquitylate
NRF2, but fail to trigger the proteosomal degradation of NRF2
(Hast et al., 2014). We hypothesize that these ‘superbinder’mutations
are defective in releasing ubiquitylated NRF2; this is somewhat
consistent with the KEAP1 cycling model recently proposed (Baird
et al., 2013). Therefore, a competitive inhibitor like R1might facilitate
the dissociation of ubiquitylated NRF2 from the ‘superbinder’ KEAP1
mutations, restoring NRF2 degradation.
Supplementary data
Supplementary data are available at PEDS online.
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